These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 26795075)

  • 41. Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
    Grosicki S; Bednarczyk M; Barchnicka A; Grosicka O
    Future Oncol; 2021 May; 17(13):1581-1591. PubMed ID: 33478270
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elotuzumab in multiple myeloma.
    Burki TK
    Lancet Oncol; 2018 Dec; 19(12):e675. PubMed ID: 30449660
    [No Abstract]   [Full Text] [Related]  

  • 43. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
    Campbell KS; Cohen AD; Pazina T
    Front Immunol; 2018; 9():2551. PubMed ID: 30455698
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
    Richardson PG; Schjesvold F; Weisel K; Moreau P; Anderson LD; White D; Rodriguez-Otero P; Sonneveld P; Engelhardt M; Jenner M; Corso A; Dürig J; Pavic M; Salomo M; Beksac M; Oriol A; Lindsay J; Liberati AM; Galli M; Robak P; Larocca A; Yagci M; Vural F; Kanate AS; Jiang R; Grote L; Peluso T; Dimopoulos M
    Eur J Haematol; 2022 Jan; 108(1):73-83. PubMed ID: 34496096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma.
    Gibiansky L; Passey C; Roy A; Bello A; Gupta M
    J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):243-57. PubMed ID: 26993283
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
    Sanchez L; Vesole DH; Richter JR; Biran N; Bilotti E; McBride L; Anand P; Ivanovski K; Siegel DS
    Br J Haematol; 2017 Feb; 176(3):440-447. PubMed ID: 27859001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
    Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma.
    Iida S; Chou T; Okamoto S; Nagai H; Hatake K; Murakami H; Takagi T; Shimizu K; Lau H; Takeshita K; Takatoku M; Hotta T
    Int J Hematol; 2010 Jul; 92(1):118-26. PubMed ID: 20559759
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
    Pozzi S; Gentile M; Sacchi S; Marcheselli R; Corso A; Cocito F; Musto P; Guarini A; Minoia C; Vincelli I; Ria R; Rivolti E; Mele G; Bari A; Mazzone C; Badiali S; Marcheselli L; Palumbo A; Morabito F
    Leuk Lymphoma; 2017 Mar; 58(3):552-559. PubMed ID: 27442600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
    Mark TM; Bowman IA; Rossi AC; Shah M; Rodriguez M; Quinn R; Pearse RN; Zafar F; Pekle K; Jayabalan D; Ely S; Coleman M; Chen-Kiang S; Niesvizky R
    Leuk Lymphoma; 2014 Dec; 55(12):2842-9. PubMed ID: 24576165
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.
    Dimopoulos M; Weisel K; van de Donk NWCJ; Ramasamy K; Gamberi B; Streetly M; Offidani M; Bridoux F; de la Rubia J; Mateos MV; Ardizzoia A; Kueenburg E; Collins S; Di Micco A; Rosettani B; Li Y; Bacon P; Sonneveld P
    J Clin Oncol; 2018 Jul; 36(20):2035-2043. PubMed ID: 29394124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.
    Eleutherakis-Papaiakovou E; Gavriatopoulou M; Ntanasis-Stathopoulos I; Kastritis E; Terpos E; Dimopoulos MA
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):921-928. PubMed ID: 31679403
    [No Abstract]   [Full Text] [Related]  

  • 53. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
    Dimopoulos MA; Christoulas D; Roussou M; Kastritis E; Migkou M; Gavriatopoulou M; Matsouka C; Mparmparoussi D; Psimenou E; Grapsa I; Efstathiou E; Terpos E
    Eur J Haematol; 2010 Jul; 85(1):1-5. PubMed ID: 20192988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Once Monthly Elotuzumab and Lenalidomide Plus Dexamethasone for Multiple Myeloma: A Multicenter Observation Study.
    Suzuki K; Matsumoto M; Hiramatsu Y; Takezako N; Tamai Y; Suzuki K
    Acta Haematol; 2023; 146(2):125-136. PubMed ID: 36538896
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.
    Cella D; McKendrick J; Kudlac A; Palumbo A; Oukessou A; Vij R; Zyczynski T; Davis C
    Ann Hematol; 2018 Dec; 97(12):2455-2463. PubMed ID: 30178193
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
    Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
    Niesvizky R; Naib T; Christos PJ; Jayabalan D; Furst JR; Jalbrzikowski J; Zafar F; Mark T; Lent R; Pearse RN; Ely S; Leonard JP; Mazumdar M; Chen-Kiang S; Coleman M
    Br J Haematol; 2007 Sep; 138(5):640-3. PubMed ID: 17686058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study.
    Oriol A; Hájek R; Spicka I; Sandhu I; Cohen YC; Gatt ME; Mariz J; Cavo M; Berdeja J; Jin K; Bar M; Das P; Motte-Mohs R; Wang Y; Perumal D; Costa LJ
    Clin Lymphoma Myeloma Leuk; 2024 Oct; 24(10):703-714. PubMed ID: 38849283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.